Viawealth LLC Grows Holdings in Medtronic PLC $MDT

Viawealth LLC boosted its stake in shares of Medtronic PLC (NYSE:MDT) by 4.1% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 19,790 shares of the medical technology company’s stock after acquiring an additional 780 shares during the quarter. Medtronic comprises 1.0% of Viawealth LLC’s investment portfolio, making the stock its 23rd biggest holding. Viawealth LLC’s holdings in Medtronic were worth $1,725,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of MDT. 1248 Management LLC purchased a new stake in shares of Medtronic in the first quarter valued at about $26,000. Twin Tree Management LP purchased a new position in shares of Medtronic in the first quarter valued at $29,000. Activest Wealth Management lifted its holdings in shares of Medtronic by 3,577.8% in the first quarter. Activest Wealth Management now owns 331 shares of the medical technology company’s stock valued at $30,000 after purchasing an additional 322 shares in the last quarter. GFG Capital LLC acquired a new stake in Medtronic during the 2nd quarter valued at $36,000. Finally, True Wealth Design LLC boosted its stake in shares of Medtronic by 49.8% during the second quarter. True Wealth Design LLC now owns 421 shares of the medical technology company’s stock valued at $37,000 after acquiring an additional 140 shares during the last quarter. 82.06% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research firms recently commented on MDT. JPMorgan Chase & Co. upped their target price on Medtronic from $90.00 to $100.00 and gave the company a “neutral” rating in a research note on Thursday, November 13th. Barclays boosted their target price on shares of Medtronic from $109.00 to $111.00 and gave the stock an “overweight” rating in a research report on Thursday, November 20th. Cowen restated a “buy” rating on shares of Medtronic in a research note on Friday, November 14th. Daiwa Capital Markets upped their target price on shares of Medtronic from $101.00 to $104.00 and gave the company a “buy” rating in a research note on Friday, September 12th. Finally, The Goldman Sachs Group set a $111.00 price objective on Medtronic and gave the stock a “neutral” rating in a research note on Wednesday, November 19th. One research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and twelve have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $109.72.

Insider Buying and Selling at Medtronic

In other news, EVP Harry Skip Kiil sold 8,605 shares of the stock in a transaction that occurred on Wednesday, September 3rd. The shares were sold at an average price of $91.58, for a total value of $788,045.90. Following the completion of the transaction, the executive vice president directly owned 35,615 shares in the company, valued at $3,261,621.70. This trade represents a 19.46% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 0.26% of the company’s stock.

Medtronic Stock Performance

Shares of MDT stock opened at $105.32 on Wednesday. Medtronic PLC has a 12-month low of $79.29 and a 12-month high of $105.60. The company has a debt-to-equity ratio of 0.54, a current ratio of 2.01 and a quick ratio of 1.50. The firm has a market capitalization of $135.09 billion, a price-to-earnings ratio of 29.01, a price-to-earnings-growth ratio of 2.42 and a beta of 0.77. The business has a 50 day simple moving average of $95.46 and a 200 day simple moving average of $91.29.

Medtronic (NYSE:MDT) last released its quarterly earnings results on Tuesday, November 18th. The medical technology company reported $1.36 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.31 by $0.05. The company had revenue of $8.96 billion during the quarter, compared to analysts’ expectations of $8.86 billion. Medtronic had a return on equity of 14.61% and a net margin of 13.63%.The company’s revenue for the quarter was up 6.6% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.26 earnings per share. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. On average, equities research analysts anticipate that Medtronic PLC will post 5.46 EPS for the current year.

Medtronic Company Profile

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.